DOI:
10.1055/s-00000017
Experimental and Clinical Endocrinology & Diabetes
LinksClose Window
References
Schwartz SL, Akinlade B, Klasen S. et al.
Safety, Pharmacokinetic, and Pharmacodynamic Profiles of Ipragliflozin (ASP1941), a Novel and Selective Inhibitor of Sodium-Dependent Glucose Co-Transporter 2, in Patients with Type 2 Diabetes Mellitus.
Diabetes Technol Ther 2011;
13: 1219-1227
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.